(Q39224445)

English

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

scientific article published on 6 April 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. (English)

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

carcinoid tumor

1 reference

based on heuristic

inferred from title

author name string

James C Yao

1

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Katherine A Guthrie

2

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Cesar Moran

3

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Jonathan R Strosberg

4

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Matthew H Kulke

5

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Jennifer A Chan

6

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Noelle LoConte

7

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Robert R McWilliams

8

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Edward M Wolin

9

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Bassam Mattar

10

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Shannon McDonough

11

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Helen Chen

12

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Charles D Blanke

13

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Howard S Hochster

14

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

language of work or name

0 references

publication date

6 April 2017

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

35

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

15

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

1695-1703

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Carcinoid--a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

15 June 2018

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

17 June 2018

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

17 June 2018

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

21 August 2018

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

21 August 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

21 August 2018

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

21 August 2018

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

21 August 2018

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455764

21 August 2018

Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28384065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/28384065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/28384065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2016.70.4072

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5455764

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39224445&oldid=2088781619"